25.05
6.23%
1.47
アフターアワーズ:
25.05
前日終値:
$23.58
開ける:
$23.6
24時間の取引高:
1.16M
Relative Volume:
1.25
時価総額:
$2.07B
収益:
$352.57M
当期純損益:
$-143.01M
株価収益率:
-5.5543
EPS:
-4.51
ネットキャッシュフロー:
$-153.40M
1週間 パフォーマンス:
+4.16%
1か月 パフォーマンス:
+10.16%
6か月 パフォーマンス:
+0.68%
1年 パフォーマンス:
-15.00%
Beam Therapeutics Inc Stock (BEAM) Company Profile
名前
Beam Therapeutics Inc
セクター
電話
857-327-8775
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
BEAM を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
BEAM | 25.05 | 2.07B | 352.57M | -143.01M | -153.40M | -4.51 |
VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-01-29 | アップグレード | JP Morgan | Neutral → Overweight |
2023-12-15 | ダウングレード | BofA Securities | Buy → Neutral |
2023-12-08 | ダウングレード | Jefferies | Buy → Hold |
2023-10-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2023-10-20 | ダウングレード | Leerink Partners | Outperform → Market Perform |
2023-03-21 | 開始されました | Bernstein | Mkt Perform |
2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
2022-12-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
2022-12-13 | 開始されました | Citigroup | Buy |
2022-06-17 | 開始されました | BMO Capital Markets | Market Perform |
2022-04-28 | 開始されました | Credit Suisse | Neutral |
2022-01-05 | 開始されました | Guggenheim | Buy |
2021-10-19 | 開始されました | SVB Leerink | Outperform |
2021-09-24 | 再開されました | Stifel | Buy |
2021-09-10 | 開始されました | BofA Securities | Buy |
2021-05-11 | 開始されました | Redburn | Buy |
2021-05-04 | 開始されました | RBC Capital Mkts | Sector Perform |
2021-03-01 | ダウングレード | Barclays | Overweight → Equal Weight |
2021-02-16 | 開始されました | Wells Fargo | Overweight |
2021-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
2021-01-06 | 開始されました | Stifel | Hold |
2020-08-05 | 開始されました | William Blair | Outperform |
2020-03-02 | 開始されました | Barclays | Overweight |
2020-03-02 | 開始されました | JP Morgan | Overweight |
2020-03-02 | 開始されました | Jefferies | Buy |
2020-03-02 | 開始されました | Wedbush | Outperform |
すべてを表示
Beam Therapeutics Inc (BEAM) 最新ニュース
Where are the Opportunities in (BEAM) - Stock Traders Daily
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Bought by Quest Partners LLC - MarketBeat
Prime Editing and CRISPR Market Trends and Growth Opportunities - openPR
Beam Therapeutics Inc. (NASDAQ:BEAM) Short Interest Up 10.3% in October - MarketBeat
Beam Therapeutics management to meet virtually with Cantor Fitzgerald - Nasdaq
Sumitomo Mitsui Trust Group Inc. Boosts Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics' SWOT analysis: base editing pioneer's stock faces market hurdles - Investing.com Australia
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Sold by Baillie Gifford & Co. - MarketBeat
FMR LLC Bolsters Position in Beam Therapeutics Inc with Recent A - GuruFocus.com
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference - Marketscreener.com
Beam Therapeutics CEO to Present at Jefferies Healthcare Conference in London | BEAM Stock News - StockTitan
Research Analysts Issue Forecasts for BEAM FY2024 Earnings - MarketBeat
Patient With Sickle Cell Disease Dies From Complications Related to Busulfan-Conditioning Following Treatment With Beam’s Base-Editing HSC Therapy BEAM-101 - CGTLive™
Trading (BEAM) With Integrated Risk Controls - Stock Traders Daily
Beam Therapeutics Inc. (NASDAQ:BEAM) President Giuseppe Ciaramella Sells 51,110 Shares - MarketBeat
Beam Therapeutics president sells $1.35 million in stock - Investing.com India
Insider Sale: President Giuseppe Ciaramella Sells Shares of Beam Therapeutics Inc (BEAM) - GuruFocus.com
Beam Therapeutics president sells $1.35 million in stock By Investing.com - Investing.com UK
ARK Investment Management LLC Has $160.01 Million Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
FY2024 EPS Estimate for Beam Therapeutics Lowered by Analyst - MarketBeat
Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch - Seeking Alpha
Beam Therapeutics (NASDAQ:BEAM) Stock Rating Upgraded by Leerink Partnrs - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Given "Buy" Rating at HC Wainwright - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Q3 2024 Earnings Call Transcript - Insider Monkey
Wedbush Expects Reduced Earnings for Beam Therapeutics - MarketBeat
William Blair Cuts Earnings Estimates for Beam Therapeutics - MarketBeat
Beam Therapeutics upgraded to Outperform from Market Perform at Leerink - Yahoo Finance
Leerink Partners Upgrades Beam Therapeutics (BEAM) - MSN
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates - MSN
Beam stock rebounds as Leerink upgrades despite fatality in gene editing trial - MSN
Beam stock rebounds as Leerink upgrades (BEAM:NASDAQ) - Seeking Alpha
Breaking Down Beam Therapeutics: 5 Analysts Share Their Views - Benzinga
This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday - Benzinga
Beam Therapeutics (NASDAQ:BEAM) Raised to "Outperform" at Leerink Partners - MarketBeat
Beam Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: P - GuruFocus.com
Beam points to positive data with key base editing asset - pharmaphorum
Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: Promising BEACON Trial Results ... - Yahoo Finance
Beam Therapeutics Reports Steady Progress in Q3 2024 - TipRanks
Patient Dies in Beam Trial of SCD Candidate; Company Cites Conditioning - Genetic Engineering & Biotechnology News
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates - MSN
Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial - AOL
Beam Is Laser-Focused On ASH As It Reports Promising Sickle Cell Data, And A Death - Citeline News & Insights
SCD phase I/II death shines Beam on ‘very real’ busulfan risk - BioWorld Online
Beam’s Base-Editing Sickle Cell Therapy Shows Early Promise, But a Fatality Overshadows Results - MedCity News
Stifel maintains $69 target on Beam Therapeutics stock By Investing.com - Investing.com Canada
JPMorgan maintains $48 target on Beam Therapeutics stock - Investing.com
Stifel maintains $69 target on Beam Therapeutics stock - Investing.com
Beam’s early base editing clinical data overshadowed by patient death - The Business Journals
Beam Therapeutics to Present Data Across Hematology - GlobeNewswire
Beam Therapeutics (NASDAQ:BEAM) Shares Gap Down After Earnings Miss - MarketBeat
Beam Therapeutics Inc (BEAM) 財務データ
収益
当期純利益
現金流量
EPS
Beam Therapeutics Inc (BEAM) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Ciaramella Giuseppe | President |
Oct 14 '24 |
Option Exercise |
2.00 |
41,754 |
83,594 |
211,370 |
Ciaramella Giuseppe | President |
Oct 14 '24 |
Sale |
26.27 |
51,110 |
1,342,752 |
160,260 |
大文字化:
|
ボリューム (24 時間):